Increase in plasma concentration of amisulpride after addition of concomitant lithium [23]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 546-549

  Bergemann, Niels ^a   Abu Tair, Fatima ^a   Kress, Kai R ^a   Parzer, Peter ^a   Kopitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DOXEPIN; LITHIUM CARBONATE; METOPROLOL SUCCINATE; MIRTAZAPINE; MOXONIDINE; NALTREXONE; PIPAMPERONE; PIRENZEPINE; RAMIPRIL; REBOXETINE; SERTRALINE; TOLTERODINE; TRIMIPRAMINE; VALPROIC ACID;

ADULT; BLOOD SAMPLING; BORDERLINE STATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SCHIZOPHRENIA; SULPIRIDE;

EID: 34548677053     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814f4dbb     Document Type: Letter

References (21)

1. Curran MP, Perry CM. Amisulpride. A review of its use in the management of schizophrenia. Drugs. 2001;61:2123-2150.
2. Lecrubier Y, Azorin M, Bottai T, et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology. 2000; 44:41-46.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60: 553-564.
4. Danion J, Rein W, Fleurot O, et al. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry. 1999;156:610-616.
5. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159: 180-190.
6. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian®): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14: 209-218.
7. Coukell AJ, Spencer CM, Benfield P. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs. 1996;6:237-256.
8. Dufour A, Desanti C. Pharmacokinetics and metabolism of amisulpride. Ann Psychiatry. 1988;3:298-305.
9. Bergemann N, Kopitz J, Kress KR, et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14:245-250.
10. Terao T, Oga T, Nozaki S, et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomised, double-blind, placebo-controlled, cross-over study. Acta Psychiatrica Scand. 1995;92:220-224.
11. Bigelow LB, Weinberger DR, Wyatt RJ. Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. Am J Psychiatry. 1981;138: 81-83.
12. Canal M, Legangneux E, van Lier JJ, et al. Lack of effect of amisulpride on the pharmacokinetics and safety of lithium. Int J Neuropsychopharmacol. 2003;6:103-109.
13. Malavasi B, Locatelli M, Ripamonti M, et al. Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid-liquid extraction or solid-phase extraction in combination with high-performance liquid chromatography and fluorescence detection. Application to pharmacokinetics. J Chromatogr B Biomed Appl. 1996;676: 107-115.
14. Bohbot M, Doare L, Diquet B. Determination of a new benzamide, amisulpride, in human plasma by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1987;416:414-419.
15. Rosenzweig P, Canal M, Patat A, et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17:1-13.
16. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group Consensus Guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
17. Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. 2000; 11:1439-1448.
18. Jorkasky DK, Amsterdam JD, Oler J, et al. Lithium-induced renal disease: a prospective study. Clin Nephrol. 1988;30:293-302.
19. Troy SM, Parker VD, Hicks DR, et al. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol. 1996;36:175-181.
20. Sugihara K, Tachibana A, Gemba M. Evidence for in vivo effect of lithium on p-aminohippurate transport in rat kidney, preliminary study. Jpn J Pharmacol. 1985;38: 127-132.
21. Breuel HP, Muller-Oerlinghausen B, Nickelsen T, et al. Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1995;33:415-419.